The Norwegian Immunotherapy in Multiple Myeloma Study

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

NCT Number	NCT06855121
Lead Sponsor	St. Olavs Hospital Collaborators: Norwegian University of Science and Technology, Haukeland University Hospital, Helse Stavanger HF, Oslo University Hospital, University Hospital, Akershus, Sykehuset i Vestfold Hospital Trust, University Hospital of North Norway, Ålesund Hospital, Norway, Helse Nord-Trøndelag HF, Sorlandet Hospital HF, Førde Hospital Trust, Molde Hospital, Bodø Hospital, Norway, Helse Fonna, Volda Hospital, Diakonhjemmet Hospital, Telemark Hospital Trust, Kristiansund Hospital, Vestre Viken Hospital Trust, Lovisenberg Diakonale Hospital, Sykehuset Innlandet HF
Conditions	Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
Enrollment	400 participants
Start Date	2025-01-15
Primary Completion	2029-01 (estimated)
Study Completion	2037-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-20